




RealRate

PHARMACEUTICAL 2017

OncoMed Pharmaceuticals Inc
Rank 171 of 313



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2017

OncoMed Pharmaceuticals Inc Rank 171 of 313

The relative strengths and weaknesses of OncoMed Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of OncoMed Pharmaceuticals Inc compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 57% points. The greatest weakness of OncoMed Pharmaceuticals Inc is the variable Research and Development, reducing the Economic Capital Ratio by 90% points.

The company's Economic Capital Ratio, given in the ranking table, is -214%, being 202% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	189,583
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	55,853
Liabilities, Non-Current	0
Other Assets	1,428
Other Compr. Net Income	240
Other Expenses	14
Other Liabilities	162,657
Other Net Income	299
Property and Equipment	4,471
Research and Development	109,713
Revenues	25,153
Selling, General and Administrative Expense	18,827

Output Variable	Value in 1000 USD
Assets	195,482
Liabilities	218,510
Expenses	128,554
Stockholders Equity	-23,028
Net Income	-103,102
Comprehensive Net Income	-102,982
Economic Capital Ratio	-214%

